These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31882645)

  • 21. Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up.
    Lin KY; Cheng CY; Li CW; Yang CJ; Tsai MS; Liu CE; Lee YT; Tang HJ; Wang NC; Lin TY; Lee YC; Lin SP; Huang YS; Zhang JY; Ko WC; Cheng SH; Hung CC;
    PLoS One; 2017; 12(6):e0179870. PubMed ID: 28665938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
    Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
    Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.
    Cardoso SW; Luz PM; Velasque L; Torres TS; Tavares IC; Ribeiro SR; Moreira RI; Veloso VG; Moore RD; Grinsztejn B
    BMC Infect Dis; 2014 Dec; 14():699. PubMed ID: 25523385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan.
    Lee YC; Hung CC; Tsai MS; Zhang JY; Wu PY; Yang SP; Luo YZ; Chang HY; Liu WC; Sun HY; Chang SC
    J Microbiol Immunol Infect; 2018 Feb; 51(1):38-44. PubMed ID: 27329131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 10-year effectiveness of combination antiretroviral treatment in perinatally HIV-infected children participating in Thailand's National Access Program.
    Aurpibul L; Puthanakit T; Sudjaritruk T; Oberdorfer P; Chotecharoentanan T; Taejaroenkul S; Wongnum N; Sirisanthana V
    Antivir Ther; 2016; 21(3):261-5. PubMed ID: 26158783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.
    Lima VD; Reuter A; Harrigan PR; Lourenço L; Chau W; Hull M; Mackenzie L; Guillemi S; Hogg RS; Barrios R; Montaner JS
    AIDS; 2015 Sep; 29(14):1871-82. PubMed ID: 26165354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study.
    Dragovic G; Smith CJ; Jevtovic D; Dimitrijevic B; Kusic J; Youle M; Johnson MA
    BMC Infect Dis; 2016 Mar; 16():106. PubMed ID: 26939611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
    Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
    Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
    J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
    Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics, mortality and outcomes at transition for adolescents with perinatal HIV infection in Asia.
    Bartlett AW; Truong KH; Songtaweesin WN; Chokephaibulkit K; Hansudewechakul R; Ly PS; Lumbiganon P; Sudjaritruk T; Nguyen LV; Do VC; Kumarasamy N; Nik Yusoff NK; Kurniati N; Fong MS; Wati DK; Nallusamy R; Sohn AH; Law MG; Mohamed TJ
    AIDS; 2018 Jul; 32(12):1689-1697. PubMed ID: 29794827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.
    de Monteynard LA; Matheron S; Gilquin J; Pavie J; de Truchis P; Grabar S; Launay O; Meynard JL; Khuong-Josses MA; Rey D; Simon A; Mahamat A; Dray-Spira R; Costagliola D; Abgrall S;
    AIDS; 2016 Sep; 30(14):2235-46. PubMed ID: 27428741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
    Manosuthi W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2015 Jan; 46(1):19-26. PubMed ID: 26513901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.
    Shibata A; McMullen E; Pham A; Belshan M; Sanford B; Zhou Y; Goede M; Date AA; Destache CJ
    AIDS Res Hum Retroviruses; 2013 May; 29(5):746-54. PubMed ID: 23289671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?
    Jarrin I; Pantazis N; Dalmau J; Phillips AN; Olson A; Mussini C; Boufassa F; Costagliola D; Porter K; Blanco J; Del Amo J; Martinez-Picado J;
    AIDS; 2015 Nov; 29(17):2323-33. PubMed ID: 26544704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Traditional Chinese Medicine Can Improve the Immune Reconstruction of HIV/AIDS Patients.
    Li X; Li H; Li C; Xia W; Li A; Li W
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):258-259. PubMed ID: 31958968
    [No Abstract]   [Full Text] [Related]  

  • 40. Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation.
    Bellissimo F; Pinzone MR; Celesia BM; Cacopardo B; Nunnari G
    Curr HIV Res; 2016; 14(6):491-496. PubMed ID: 27074946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.